Tyme Technologies : Inc - Corporate Presentation

T Y M E I N C . C O M / N A S D A Q : T Y M E

S c i e n t i f i c S o l u t i o n s W i t h o u t C o m p r o m i s e

Corporate Presentation

J a n u a r y 2 0 2 2

T Y M E I N C . C O M

Safe Harbor Statement

In addition to historical information, this presentation contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this presentation include, without limitation, statements regarding our drug candidates (including SM-88 and TYME- 18) and their clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned preclinical or clinical trials, including the proposed TYME-19proof-of-concept study, preliminary data results and the therapeutic design and mechanisms of our drug candidates. The words "believes," "expects," "hopes," "may," "will," "plan," "intends," "estimates," "could," "should," "would," "continue," "seeks," "anticipates," and similar expressions (including their use in the negative) are intended to identify forward-looking statements. Forward-looking statements can also be identified by discussions of future matters such as: the effect of the novel coronavirus (COVID-19) pandemic and the associated impact on the national and global economy as well as impacts on the Company's ongoing clinical trials and ability to analyze data from those trials; the cost of development and potential commercialization of our lead drug candidate and of other new products; expected releases of interim or final data from our clinical trials; possible collaborations; and the timing, scope, status, objectives of our ongoing and planned trials; the success of management transitions; and other statements that are not historical. The forward-looking statements contained in this presentation are based on management's current expectations and projections which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any historical results and future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include but are not limited to: the severity, duration, and economic impact of the COVID-19 pandemic; that the information is of a preliminary nature and may be subject to change; uncertainties inherent in the cost and outcomes of research and development, including the cost and availability of acceptable-quality clinical supply, and in the ability to achieve adequate start and completion dates, as well as uncertainties in clinical trial design and patient enrollment, dropout or discontinuation rates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final data from any clinical trials may differ from prior or preliminary study data; final results of additional clinical trials that may be different from the preliminary data analysis and may not support further clinical development; that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 or other drug candidates may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88 or other drug candidates; the ability of TYME and its collaborators to develop and realize collaborative synergies; competitive developments; and the factors described in the section captioned "Risk Factors" of TYME's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on June 10, 2021 as well as subsequent reports we file from time to time with the U.S. Securities and Exchange Commission available at www.sec.gov.

2

T Y M E I N C . C O M

TYME: Compelling Investment Highlights

Key 2021 accomplishments

• Implemented new strategic plan
• Broadened management team with extensive biopharmaceutical industry experience
• Diversified pipeline with launch of OASIS breast cancer trial; enrolled first patient
• Initiated biomarker and MOA programs
• Raised $100M, establishing appropriate capital to advance pipeline and key strategic initiatives

Advancing robust pipeline in multiple indications

• Newly launched OASIS trial - phase 2 metastatic HR+/HER2- breast cancer trial with Georgetown University
• PRECISION PROMISE trial - phase 2/3 trial in metastatic pancreatic cancer
• HopES trial - phase 2 trial in advanced sarcomas
• Tyme-19oral therapeutic - advancing novel oral mechanism for COVID-19

New biomarkers initiative

• Data driven approach to identify strategic development opportunities including combination approaches
• Focuses on activity previously observed in our platform therapy across 15 cancer types as seen in first-in- human study and in a compassionate use program
• Working with Evotec and pre-eminent medical institutions: Georgetown University, NYU Medical Center, and the Mayo Clinic

Well-funded to advance programs

• $96.6M of cash and marketable securities as of 9/30/2021	3

T Y M E I N C . C O M

		Pipeline
P R O G R A M	I N D I C A T I O N	P R E C L I N I C A L	P H A S E 1	P H A S E 2	P H A S E 3
O N C O L O G Y
	Pancreatic Cancer				PRECISION
				PROMISE
SM-88	Breast Cancer			OASIS
Oral	(HR+/HER2-)
	Metastatic Sarcomas			HopES
SM-88i	Multiple Oncology Indications
Injectable	(Alternative Formulation)
TYME-18	Solid Tumors
Intra-tumoral
TYME-T3
Tumor Targeting	Solid Tumors
Technology
V I R A L

TYME-19	COVID-19
Oral

4

Targeting a Fundamental Cancer Process

SM-88

SM-88	3	Normal cells do not
	consume SM-88 or
SM-		related amino acids.
88	Oral SM-88

• delivery

-88 SM

SM-88 disrupting protein synthesis alters tumor immune environment and causes

-88 SM

SM-88

SM-88

SM- 88

Cancer cells selectively consume large amounts of certain amino

• acids. This is a fundamental process in majority of cancers.

SM-88

-88 SM

CANCER CELL

- SM 88

• oxidative stress which ultimately leads to cell death.

5